Cardiff Oncology Inc. (CRDF)
3.29
-0.15 (-4.36%)
At close: Mar 28, 2025, 3:59 PM
3.30
0.39%
Pre-market: Mar 31, 2025, 06:00 AM EDT
Cardiff Oncology Income Statement
| Year | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 | FY10 | FY09 | FY05 | FY04 |
| Revenue | 683K | 488K | 386K | 359K | 365.99K | 245K | 378K | 505K | 381K | 313K | 280K | 259.25K | 450K | 257.7K | 265.67K | 650K | n/a | n/a |
| Cost of Revenue | n/a | n/a | 200K | 500K | 11.23M | 11.16M | 597K | 1.81M | 1.73M | 629K | 15K | 3.48M | 1.92M | n/a | n/a | n/a | n/a | n/a |
| Gross Profit | 683K | 488K | 186K | -141K | -10.87M | -10.92M | -219K | -1.31M | -1.35M | -316K | 265K | -3.22M | -1.47M | 257.7K | 265.67K | 650K | n/a | n/a |
| Operating Income | -48.65M | -45.41M | -39.9M | -28.86M | -19.09M | -16.68M | -17.05M | -25.6M | -40.15M | -25.27M | -14.95M | -10.69M | -4.85M | -2.98M | -5.38M | -2.39M | -8M | -5.38M |
| Interest Income | 3.26M | 4.07M | 1.58M | 264K | 89.81K | 234.17K | 219.43K | 147.88K | n/a | 57.26K | 12K | 3.66K | n/a | 171.00 | 182.00 | n/a | 129.16K | n/a |
| Pretax Income | -45.45M | -41.44M | -38.7M | -28.29M | -19.31M | -16.41M | -16.46M | -24.91M | -39.2M | -27.47M | -14.32M | -11.81M | -11.57M | -2.28M | -5.33M | -2.48M | -7.84M | -5.37M |
| Net Income | -45.43M | -41.44M | -37.51M | -27.74M | -19.28M | -16.15M | -16.46M | -24.91M | -39.2M | -27.47M | -14.32M | -11.81M | -11.57M | -2.24M | -5.45M | -2.48M | -7.84M | -5.37M |
| Selling & General & Admin | 12.48M | 13.04M | 13.18M | 11.84M | 8.22M | 5.76M | 8.01M | 14.23M | 23M | 14.36M | 8.54M | 7M | 3.38M | 2.32M | 1.95M | 2.22M | 2.53M | 651.7K |
| Research & Development | 36.85M | 32.86M | 27.11M | 17.38M | 11.24M | 11.16M | 8.16M | 7.88M | 15.01M | 10.59M | 6.67M | 3.95M | 1.92M | 910.68K | 3.69M | n/a | 1.88M | 619.63K |
| Other Expenses | n/a | n/a | -383K | 15K | -28.24K | 2K | -237K | -170K | -145K | -3K | n/a | n/a | 4K | n/a | n/a | 830K | n/a | n/a |
| Operating Expenses | 49.33M | 45.9M | 40.29M | 29.21M | 19.45M | 16.92M | 16.17M | 22.11M | 38.01M | 24.96M | 15.21M | 10.95M | 5.3M | 3.23M | 5.64M | 3.05M | 4.41M | 1.27M |
| Interest Expense | n/a | n/a | 1.58M | n/a | 1.52K | n/a | 25.41K | 886K | 1.38M | 1.53M | 843K | 17K | n/a | 56.64K | 115.58K | -90K | n/a | n/a |
| Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | 417.00 | 2.73M | 11.52M | 6.44M | 2.73M | 245.47K | 506.53K | n/a | n/a | n/a | n/a | n/a |
| Cost & Expenses | 49.33M | 45.9M | 40.29M | 29.21M | 19.45M | 16.92M | 16.77M | 23.93M | 39.74M | 25.59M | 15.22M | 10.95M | 5.3M | 3.23M | 5.64M | 3.05M | 8M | 1.27M |
| Income Tax | n/a | n/a | -1.2M | -549K | -26.73K | -262K | 617.64K | 716K | -296K | 1.82M | 608.19K | 17K | 6.68M | -737.59K | 69.85K | -180K | n/a | n/a |
| Shares Outstanding (Basic) | 47.65M | 44.68M | 43.6M | 39.03M | 20.87M | 5.97M | 2.33M | 481.67K | 419.1K | 363.92K | 262.56K | 234.94K | 181.09K | 134.88K | 99.43K | 70K | 18.47M | 14.58M |
| Shares Outstanding (Diluted) | 47.65M | 44.68M | 43.6M | 39.03M | 20.87M | 5.97M | 2.33M | 481.67K | 420.57K | 367.39K | 264.87K | 235.81K | 181.49K | 134.88K | 99.43K | 70K | 18.47M | 14.58M |
| EPS (Basic) | -0.95 | -0.93 | -0.86 | -0.71 | -0.92 | -2.7 | -7.06 | -51.71 | -93.54 | -75.49 | -54.56 | -50.27 | -63.87 | -16.6 | -54.81 | -35.43 | -0.42 | -0.37 |
| EPS (Diluted) | -0.95 | -0.93 | -0.86 | -0.71 | -0.92 | -2.7 | -7.06 | -51.71 | -93.22 | -74.77 | -54.08 | -50.09 | -63.73 | -16.6 | -54.81 | -35.43 | -0.42 | -0.37 |
| EBITDA | -48.65M | -45.01M | -39.67M | -28.4M | -18.84M | -15.92M | -15.7M | -22.82M | -36.76M | -24.89M | -14.71M | -11.66M | -11.53M | -2.1M | -5.37M | -2.17M | -8M | -5.38M |
| Depreciation & Amortization | n/a | 398K | 200K | 500K | 466.01K | 494.23K | 736.09K | 1.05M | 1.07M | 378.71K | 234.81K | 130.52K | 37.84K | 10.29K | 8.39K | 50K | n/a | n/a |